Skip to content
  1. Home
  2. Latest news
  3. Health & wellness
  4. Baby’s first breath: How one landmark program in China has saved 150,000 newborns
Helping Babies Breath Hi Res

Baby’s first breath: How one landmark program in China has saved 150,000 newborns

Sixty seconds. That’s how much time a healthcare professional has to ensure that a newborn takes a first breath in order for that baby to have a healthy start in life.

But far too often newborns aren’t able to take that first breath on their own.

It’s a condition known as birth asphyxia—and it’s one of the world’s leading causes of infant mortality. In fact, some 10 million newborns worldwide have difficulty breathing at birth each year. And in China, over 73,000 babies died from the complication in 2004 alone.

So to help change that alarming statistic, Johnson & Johnson formed a first-of-its-kind public-private partnership with the Chinese government and other professional associations to launch the “Freedom of Breath, Fountain of Life” training program.

The goal: help prevent birth asphyxia in Chinese hospitals by ensuring that every delivery had at least one person trained in neonatal resuscitation present.

Today, as the program marks its 10-year anniversary, the initiative has saved an estimated 150,000 newborns across the country.

And that’s just one heartwarming stat.

As you’ll see in this infographic, there are more inspiring facts, figures and stories behind the formation of this landmark partnership—and the many children to whom it’s given a healthy start.

Cina NRP Final Infographic

null

More from Johnson & Johnson

Terra Kremer, Ph.D., is on a mission to create self-sterilizing surgical tools

Since its launch, Johnson & Johnson has focused on helping make surgeries safer. Learn how this analytical microbiologist and her team are continuing in that tradition with a digital app that aims to change the way medical devices are designed and sterilized.

What is lupus?

Up to 5 million people worldwide live with this complex autoimmune condition, which is more prevalent in women and has a greater disease severity in Latin Americans and patients of African ancestry. Learn how Johnson & Johnson is working to innovate treatments for autoimmune diseases.

This scientist develops targeted treatments for cancer—here’s what drives and inspires him

Learn more about Zhao, his partnership with Johnson & Johnson and antibody-drug conjugates—a new type of cancer therapy that targets and kills cancer cells without harming healthy cells.